Trial
NCT04915950
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Condition
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intervention
Temanogrel
Why stopped
Business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-22